Your browser doesn't support javascript.
loading
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Maddocks, Kami; Christian, Beth; Jaglowski, Samantha; Flynn, Joseph; Jones, Jeffery A; Porcu, Pierluigi; Wei, Lai; Jenkins, Cynthia; Lozanski, Gerard; Byrd, John C; Blum, Kristie A.
  • Maddocks K; Division of Hematology, Department of Internal Medicine.
  • Christian B; Division of Hematology, Department of Internal Medicine.
  • Jaglowski S; Division of Hematology, Department of Internal Medicine.
  • Flynn J; Division of Hematology, Department of Internal Medicine.
  • Jones JA; Division of Hematology, Department of Internal Medicine.
  • Porcu P; Division of Hematology, Department of Internal Medicine.
  • Wei L; Center for Biostatistics.
  • Jenkins C; Clinical Trials Office, Arthur G. James Comprehensive Cancer Center and Research Institute, and.
  • Lozanski G; Department of Pathology, The Ohio State University, Columbus, OH.
  • Byrd JC; Division of Hematology, Department of Internal Medicine.
  • Blum KA; Division of Hematology, Department of Internal Medicine.
Blood ; 125(2): 242-8, 2015 Jan 08.
Article en En | MEDLINE | ID: mdl-25355819
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article